10-QFiled 9 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
The nightly ledger
Every 8-K, 10-Q and 10-K that AIR's companies filed on SEC EDGAR, and what each one changed in AIR's read. Material filings first, newest first — never ordered by price. For 8-K filing alerts, follow a company and turn on filing emails.
By event type: Acquisitions · Major contracts
Seven-day window, 1 week back · Material filings: 447 · All filings: 661
Monday 9 Nov264 filings read · 204 material
10-QFiled 9 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
10-QFiled 9 Nov 2026Biotech
Immunome Inc.IMNM
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 9 Nov 2026Industrials
Novanta IncNOVT
Quarterly report (10-Q), period ending 2 Oct 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 9 Nov 2026All industries
Office Properties Income TrustOPI
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 9 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 9 Nov 2026All industries
Paysign, Inc.PAYS
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $30.8M (+43% YoY) driven by pharma affordability growth (109.8% increase). Operating margin tripled to 23.8%. Company raised full-year 2026 guidance for gross margin, net income, EPS, and Adjusted EBITDA despite announced loss of 113 plasma centers.
AIR measured this for the first time; no change to report.
Market attention has faded.
The price trend weakened.
8-KFiled 9 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 shows 67% YTD sales increase and 26% captured-pound growth. Lost Creek and Shirley Basin ramping; exploration accelerating. Cash costs remain low at $40.40/lb. Inventory deferrals manage near-term delivery timing.
No notable change in AIR's read.
10-QFiled 9 Nov 2026Banks
Orange County Bancorp, Inc. /DE/OBT
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
8-KFiled 9 Nov 2026All industries
WEBTOON Entertainment Inc.WBTN
8-K · Item 2.02 — Results of operations
WEBTOON reported Q3 2026 revenue of $362.8M (down 4.0% YoY; up 0.2% constant currency), net loss of $7.5M, and Adjusted EBITDA of $2.2M. Results within guidance. Company guides Q4 2026 constant currency revenue growth of 9-12% and expects return to double-digit growth.
No notable change in AIR's read.
10-QFiled 9 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
The price trend weakened.
10-QFiled 9 Nov 2026All industries
Bain Capital Specialty Finance, Inc.BCSF
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 9 Nov 2026All industries
8-K · Item 2.02 — Results of operations
USA Rare Earth reported Q3 2026 results with multiple operational milestones: Serra Verde Stage 1 completed on time/budget with commercial MREC shipments begun; first NdFeB magnet sales from Stillwater facility; rare earth oxide samples produced; Blacksburg facility groundbreaking ($1.2B investment); $1.2B cash position.
No notable change in AIR's read.
8-KFiled 9 Nov 2026Biotech
Zymeworks Inc.ZYME
8-K · Item 2.02 — Results of operations
Zymeworks raised 2026 revenue guidance to $337–351M (from $278–292M) and Adjusted EBITDA to $176–190M (from $114–128M). Ziihera received FDA approval for first-line GEA, generating $250M milestone. Roche collaboration for ZW209 announced with up to $813M in potential payments.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 9 Nov 2026All industries
Corebridge Financial, Inc.CRBG
8-K · Item 1.01 — Material agreement
Corebridge Financial entered into a share repurchase agreement with Argon Holdco LLC to repurchase approximately $110 million of common stock at $34.09 per share, expected to close November 10, 2026.
The shares became cheaper on AIR's value read.
8-KFiled 9 Nov 2026All industries
Lineage, Inc.LINE
8-K · Item 2.02 — Results of operations
Q3 2026 results show revenue decline of 1.2%, GAAP net loss of $173M, adjusted EBITDA down 7.0%, and AFFO per share down 14.1%. Management cites temporary headwinds from oil prices, trucking constraints, and tariff uncertainty, with guidance reduced for full-year 2026.
Market attention has faded.
The price trend weakened.
8-KFiled 9 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
AbCellera announced positive Phase 2 data for ABCL635 showing significant efficacy in vasomotor symptoms with favorable safety. Raised $200M, expanding liquidity to ~$900M. Added three new pipeline programs and achieved Phase 1 readout for ABCL575.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 9 Nov 2026Software / SaaS
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 9 Nov 2026Industrials
Powerfleet, Inc.AIOT
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 9 Nov 2026Banks
Popular, Inc.BPOP
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
The gap closed as the filings read less positively.
10-QFiled 9 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 9 Nov 2026All industries
8-K · Item 1.01 — Material agreement
Surgery Partners amended its merger agreement with HealthSpan Partners (Bon Secours Mercy Health affiliate), increasing merger consideration to $25.00 per share cash, plus potential ticking fees up to $1.61 per share if closing delayed past March 1, 2027, representing enterprise value up to ~$6.0 billion.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 9 Nov 2026Industrials
Plug Power IncPLUG
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 9 Nov 2026All industries
Select Water Solutions, Inc.WTTR
8-K · Item 2.02 — Results of operations
Q3 2026 revenue grew 28% YoY to $412M; net income increased to $23M; Adjusted EBITDA rose 57% to $93.5M. Water Infrastructure segment hit record $110M revenue (+40% YoY). Company completed Peak Rentals divestment and closed Pilot Water acquisition post-quarter.
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
8-KFiled 9 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Surgery Partners announced amended merger agreement with HealthSpan Partners at $25/share ($6B enterprise value) following competing proposal. Q3 revenue declined 0.8% YoY; Adjusted EBITDA fell to $132.7M from $136.4M. Net loss of $21.1M. Same-facility revenue grew 6.0% but overall metrics weakened.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 9 Nov 2026Banks
Green Dot CorpGDOT
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became dearer on AIR's value read.
The price trend weakened.
8-KFiled 9 Nov 2026Biotech
Neurogene Inc.NGNE
8-K · Item 2.02 — Results of operations
Neurogene reported Q3 2026 results with NGN-401 Rett syndrome trial on track for topline data in H2 2027. PPQ manufacturing runs expected complete by year-end 2026. Strong cash position ($359.7M) funds operations into Q1 2029. Safety profile remains favorable in 35 dosed participants.
Progress is running ahead of attention.
8-KFiled 9 Nov 2026Industrials
Babcock & Wilcox Enterprises, Inc.BW
8-K · Item 2.02 — Results of operations
B&W reported Q3 2026 revenue of $291M (+109% YoY), net income $94M, EPS $0.61 (+103% YoY), and adjusted EBITDA $17.7M (+88% YoY). Backlog surged 571% to $2.5B; pipeline exceeds $16B. Issued 2027 adjusted EBITDA guidance of $125–$140M.
More of the market is starting to notice.
Progress is running ahead of attention.
8-KFiled 9 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q2 FY2027 revenue grew 42.9% YoY to $89.6M with gross margin expansion to 41.0%. Non-GAAP net income $9.8M ($0.25/share) vs. prior-year loss. Record ~$100M backlog and major hyperscale Scalar i7 Raptor order secured.
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 9 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 earnings exceeded prior year with $123M net income and $435M Adjusted EBITDA. Company reaffirmed 2026 guidance, initiated 2027 guidance ($520–590M CAFD), and announced three committed growth investments (Swan Solar, Honeycomb 2, Heartland) totaling ~$379M with ~$36M annual CAFD contribution.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 9 Nov 2026All industries
8-K · Item 2.02 — Results of operations
GeneDx reported Q3 2026 revenue of $123.1M (+5% YoY), with exome/genome revenue at $110.4M (+12% YoY). Volume growth of 25% YoY and 28% accession growth. Adjusted gross margin expanded to 72%, adjusted net income $8.6M. Full-year guidance maintained at $475–$490M.
The shares became cheaper on AIR's value read.
8-KFiled 9 Nov 2026Software / SaaS
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $9.5M exceeded H1 2026 total ($9.2M), driven by acquired businesses (LSI, NuCrypt, NHanced). Company maintains $1.3B cash position and $39.1M backlog. New pharma partnership and university collaboration announced.
No notable change in AIR's read.
8-KFiled 9 Nov 2026Software / SaaS
Ceva IncCEVA
8-K · Item 2.02 — Results of operations
Q3 2026: Total revenues $29.1M (+2% YoY), royalty revenues $12.7M (+18% sequentially), record AI licensing (>35% of licensing). Multi-year smartphone modem ramp ahead. Device shipments matched all-time record at 623M units.
Progress is running ahead of attention.
10-QFiled 9 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
10-QFiled 9 Nov 2026Software / SaaS
Ceva IncCEVA
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 9 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 9 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 9 Nov 2026Industrials
Mesa Laboratories Inc /Co/MLAB
8-K · Item 2.02 — Results of operations
Mesa Labs reported Q2 FY2027 results with 2.6% revenue growth, 77.6% operating income increase, and 75.3% net income growth. Company issued first full-year guidance ($250–255M revenue, $66–68M adjusted EBITDA) and announced $9.3M cost-reduction plan with $4.3M reinvestment.
No notable change in AIR's read.
8-KFiled 9 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $35.1M (+70% YoY) driven by HEPZATO KIT sales of $32.7M (+69% YoY). Net income $7.0M vs $0.8M prior year. Company raised 2026 revenue guidance to $115–117M, reflecting ≥41% HEPZATO volume growth. 33 active treatment centers; Phase 2 DELUMA trial ongoing.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 9 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 9 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 9 Nov 2026Software / SaaS
8-K · Item 2.02 — Results of operations
Life360 reported Q3 2026 results with 40% YoY revenue growth to $174.1M, record third-quarter Paying Circle additions (188K), and 107.7M MAU. Raised FY26 revenue guidance to $665–681M. Advertising revenue surged 250% YoY post-Nativo acquisition.
Market attention has faded.
Progress is running ahead of attention.
10-QFiled 9 Nov 2026Industrials
Babcock & Wilcox Enterprises, Inc.BW
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
10-QFiled 9 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 9 Nov 2026Banks
8-K · Item 2.02 — Results of operations
MARA reported Q3 2026 results showing revenue decline but significant net income and EBITDA growth, $1.4B debt reduction (37% of total), FERC approval for Long Ridge power plant, Exaion's $79M GPU contract, and authorization of $500M share repurchase program.
The shares became dearer on AIR's value read.
8-KFiled 9 Nov 2026Biotech
Immunovant, Inc.IMVT
8-K · Item 2.02 — Results of operations
IMVT-1402 600 mg met primary endpoint in difficult-to-treat RA trial (92.5% vs 75.6% placebo, p=0.0139). Strong exploratory ACR50/ACR70 responses. Good safety profile. FDA discussions planned. Sjögren's indication deprioritized.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 9 Nov 2026All industries
Dole plcDOLE
8-K · Item 2.02 — Results of operations
Q3 2026 revenue grew 3.8% to $2.4B and adjusted EBITDA rose 4.1% to $84.1M, but full-year 2026 guidance was reduced to $380–390M from ~$400M due to elevated fuel/shipping costs and adverse weather impacts on fruit supply.
No notable change in AIR's read.
8-KFiled 9 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Hallador reported Q3 2026 results with sequential revenue growth and secured $600M construction financing for Turtle Creek 460-MW natural gas project. Forward sales increased 26% to $3.0B; targeting FID by year-end 2026 and commercial operation H2 2028.
No notable change in AIR's read.
8-KFiled 9 Nov 2026Industrials
Powerfleet, Inc.AIOT
8-K · Item 2.02 — Results of operations
Powerfleet reported Q2 FY2027 record revenue of $115.7M (4% sequential growth), services revenue up 7% YoY, and profit from operations of $1.4M. Company secured device financing facility with Rand Merchant Bank and launched two new AI products (Unity Foresight, Unity Asset Intelligence). Affirmed full-year guidance.
Market attention has faded.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 9 Nov 2026All industries
National Energy Services Reunited Corp.NESR
8-K · Items 2.02, 8.01 — Results of operations
NESR reported Q3 2026 revenue of $504.7M (+70.9% YoY), net income of $34.3M (+93.5% YoY), and diluted EPS of $0.33 (+83.3% YoY). Company declared $0.10/share dividend and completed debt refinancing.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 9 Nov 2026All industries
Lincoln Educational Services CorpLINC
8-K · Item 2.02 — Results of operations
Lincoln Educational Services reported Q3 2026 results with strong operational performance: student starts +14.2%, revenue +12.6% to $159.2M, adjusted EBITDA +30.8% to $17.4M, net income +24.1%. Company raised full-year revenue guidance and narrowed student start guidance to 10-12%.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 9 Nov 2026Software / SaaS
Coursera, Inc.COUR
8-K · Items 1.01, 3.03 — Material agreement
Coursera adopted a limited-duration stockholder rights plan in response to a shareholder accumulating 14.7% ownership. The plan triggers at 15% ownership, allowing other shareholders to purchase stock at 50% discount or forces exchange. Rights expire November 7, 2027.
The filings read less positively.
The gap closed as the filings read less positively.
10-QFiled 9 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
The gap narrowed as the filings read less positively.
10-QFiled 9 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 9 Nov 2026Banks
Sharplink, Inc.SBET
8-K · Item 2.02 — Results of operations
Sharplink reported Q3 2026 revenue up 24% YoY to $13.5M and net income of $751.4M ($3.45/diluted share), driven by unrealized crypto gains of $676.7M and realized gains of $75.2M. ETH holdings reached ~892.7K ETH; completed $200M Lido staking allocation.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 9 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 9 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
10-QFiled 9 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
10-QFiled 9 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 9 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
10-QFiled 9 Nov 2026Banks
Esquire Financial Holdings, Inc.ESQ
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became dearer on AIR's value read.
8-KFiled 9 Nov 2026Industrials
Plug Power IncPLUG
8-K · Item 2.02 — Results of operations
Plug Power reported Q3 2026 revenue of ~$201M (+13% YoY), gross margin improved ~65 percentage points to ~(3%), and record-low net cash usage of ~$28M. Material handling deployments doubled YoY; major electrolyzer orders secured including 280 MW Arcadia eFuels deal.
Progress is running ahead of attention.
10-QFiled 9 Nov 2026Banks
Pra Group IncPRAA
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 9 Nov 2026Biotech
8-K · Items 2.02, 8.01 — Results of operations
Phase 3 CoMpass trial fully enrolled with all 108 participants completing treatment; topline data expected 2H 2027. Established CDMO partnership with designated manufacturing capacity. Cash runway extended to 1H 2029. Organizational restructuring completed.
More of the market is starting to notice.
The price trend strengthened.
10-QFiled 9 Nov 2026All industries
Cbl & Associates Properties IncCBL
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 9 Nov 2026All industries
Somnigroup International Inc.SGI
8-K · Items 2.02, 8.01 — Results of operations
SGI reported Q3 2026 record adjusted EPS of $1.04 (+9.5%), completed Leggett & Platt acquisition, improved leverage to 2.69x, and raised full-year 2026 adjusted EPS guidance to $2.85–$2.95 range (~7% growth vs. 2025).
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
10-QFiled 9 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 9 Nov 2026All industries
8-K · Item 2.02 — Results of operations
HighPeak reported Q3 2026 production above guidance (44.2 MBoe/d), generated $22.4M free cash flow, reduced debt by $30M, and announced a transformational $450M preferred equity investment with new $800M credit facility to refinance $1.2B term loan.
Market attention has faded.
Progress is running ahead of attention.
10-QFiled 9 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The price trend weakened.
10-QFiled 9 Nov 2026All industries
KEMPER CorpKMPR
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 9 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
ImmunityBio reported Q3 2026 net product revenue of $48.7M (53% YoY growth) and 9M revenue of $143.6M (92% YoY growth). FDA expanded ANKTIVA approval for BCG-unresponsive NMIBC papillary-only tumors; BCG-naïve trial met primary endpoint; Israel approval and first European patient treated.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 9 Nov 2026All industries
RadNet, Inc.RDNT
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
8-KFiled 9 Nov 2026Software / SaaS
Trump Media & Technology Group Corp.DJT
8-K · Item 2.02 — Results of operations
Q3 2026 revenue grew 205% YoY to $3.0M, driven by Truth API data licensing ($1.8M) and Truth+ subscriptions. S-4 merger registration with TAE declared effective; shareholder vote scheduled December 14. Balance sheet shows $2.5B total assets, $2.3B financial assets. Legal costs declined sharply.
Progress is running ahead of attention.
8-KFiled 9 Nov 2026All industries
Gladstone Investment CorporationdeGAIN
8-K · Item 2.02 — Results of operations
Q2 2026 net investment income fell 69.6% QoQ to $4.8M ($0.12/share) from $15.9M ($0.40/share), driven by lower investment income and higher expenses. Portfolio expanded to 31 companies with $1.43B in investments.
The gap narrowed as the filings read less positively.
8-KFiled 9 Nov 2026All industries
RadNet, Inc.RDNT
8-K · Item 2.02 — Results of operations
RadNet reported Q3 2026 record revenue of $638.3M (+22.1% YoY) and adjusted EBITDA of $105.0M (+23.8% YoY). Company raised full-year 2026 guidance for Imaging Center revenue, adjusted EBITDA, and free cash flow. Digital Health segment revenue grew 32.6% but EBITDA declined 11.8%.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
8-KFiled 9 Nov 2026Biotech
Immunome Inc.IMNM
8-K · Item 2.02 — Results of operations
Immunome achieved multiple clinical and regulatory milestones: varegacestat FDA PDUFA date set for April 2027 with EMA MAA validation; IM-1021 shows objective responses across B-cell lymphoma cohorts; IM-1340 IND cleared for Phase 1 initiation by year-end. Cash position of $461.6M funds operations into 2028.
Progress is running ahead of attention.
The price trend weakened.
10-KFiled 9 Nov 2026All industries
Annual report (10-K), FY2026
The reported numbers improved.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 9 Nov 2026All industries
Natural Gas Services Group IncNGS
8-K · Items 2.02, 8.01 — Results of operations
NGS reported Q3 2026 results with rental revenue up 41.9% YoY to $58.9M and Adjusted EBITDA up 42.2% to $29.6M. Company raised full-year 2026 Adjusted EBITDA guidance to $105–108M and increased quarterly dividend to $0.16/share.
Progress is running ahead of attention.
8-KFiled 9 Nov 2026All industries
Aaon, Inc.AAON
8-K · Items 2.02, 4.02 — Results of operations
AAON restated Q1 and Q2 2026 financial statements due to errors in revenue recognition (percent-of-completion method) and software subscription accounting. A material weakness in internal controls was identified. Despite strong Q3 operational results and raised FY2026 guidance, the restatement and control deficiency represent significant governance concerns.
The filings read less positively.
The gap closed as the filings read less positively.
The price trend strengthened.
8-KFiled 9 Nov 2026All industries
KEMPER CorpKMPR
8-K · Item 2.02 — Results of operations
Q3 2026 net income of $52.4M ($0.88/share) vs. Q3 2025 loss of $21.0M ($-0.34/share). Adjusted operating income $59.9M ($1.01/share) vs. $20.4M ($0.33/share). Personal Auto profitability improved; California Combined Ratio improved 12 points since Q1 2026.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 9 Nov 2026All industries
National Health Investors IncNHI
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The price trend weakened.
8-KFiled 9 Nov 2026All industries
National Health Investors IncNHI
8-K · Item 2.02 — Results of operations
Market attention has faded.
The price trend weakened.
8-KFiled 9 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 revenue up 30% YoY to $129.1M; Adjusted EBITDA up 59% to $34.2M with 480bps margin expansion. Since January, secured $1.7B in multi-year contracts representing 10,000+ beds. WHS segment revenue up 116% YoY. Company reaffirms full-year 2026 outlook and projects $750M+ revenue and $300M+ Adjusted EBITDA exiting 2027.
Progress is running ahead of attention.
10-QFiled 9 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 9 Nov 2026Biotech
Structure Therapeutics Inc.GPCR
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 9 Nov 2026All industries
Select Water Solutions, Inc.WTTR
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
8-KFiled 9 Nov 2026Biotech
Annexon, Inc.ANNX
8-K · Item 2.02 — Results of operations
Annexon reports Q3 2026 results with two late-stage registrational programs advancing: tanruprubart BLA submission anticipated Q4 2026 for GBS; vonaprument ARCHER II Phase 3 Month 15 endpoint assessment expected Q4 2026 for GA. Cash runway extended to 2028.
Progress is running ahead of attention.
8-KFiled 9 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $410M (+88% YoY, +19% QoQ) exceeded guidance high-end. Non-GAAP gross margin improved 60bps to 57.6%. Backlog exceeded $1.3B. Q4 guidance projects $430–450M revenue with strong margins. CEO cites robust AI/HPC demand.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 9 Nov 2026All industries
Crescent Capital BDC, Inc.CCAP
8-K · Item 2.02 — Results of operations
Q3 2026 earnings: NII $0.37/share, net income $0.27/share, NAV $17.72. Board authorized $50M share repurchase; Sun Life plans additional $25M purchase. Q4 dividend declared at $0.34/share.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 9 Nov 2026Biotech
Definium Therapeutics, Inc.DFTX
8-K · Item 2.02 — Results of operations
Definium reported positive Phase 3 topline results for DT120 ODT in two GAD studies (Voyage and Panorama), met primary and key secondary endpoints with statistical significance. Received FDA Breakthrough Therapy Designation for MDD. DT402 showed positive Phase 2a results in ASD. Cash position strengthened to $1.05B.
Progress is running ahead of attention.
10-QFiled 9 Nov 2026Biotech
Definium Therapeutics, Inc.DFTX
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 9 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Trevi initiated Phase 3 OCEAN-2 trial for IPF-related chronic cough; achieved FDA alignment on non-IPF ILD program with Phase 2 expected Q1 2027; received USPTO Notice of Allowance for patent covering nalbuphine ER dosing in hepatically impaired patients (expiring 2041); cash runway extended into 2030.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 9 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 9 Nov 2026Biotech
Xenon Pharmaceuticals Inc.XENE
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 9 Nov 2026Industrials
Novanta IncNOVT
8-K · Item 2.02 — Results of operations
Q3 2026 revenue grew 23% YoY to $305M; Adjusted EBITDA increased 38% to $80.3M with margin expansion of 290bps. Organic growth 9.9%. Customer bookings up 29% to $543M backlog. FY2026 guidance raised; 2027 revenue growth expected >15%.
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 9 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
10-QFiled 9 Nov 2026Biotech
Neurogene Inc.NGNE
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 9 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q1 FY2027 net sales declined 12% YoY to $129.6M; operating margin compressed to 1.3% from 6.8% due to tariffs, lower traffic, and soft housing market. Adjusted EPS fell 77% to $0.10 from $0.43.
No notable change in AIR's read.
8-KFiled 9 Nov 2026All industries
QXO, Inc.QXO
8-K · Item 2.02 — Results of operations
QXO reported Q3 2026 preliminary results: net sales of $4.90B (up 79% YoY), GAAP net loss improved to $123M from $139M, and Adjusted EBITDA grew 85% to $557M. Growth driven by Kodiak and TopBuild acquisitions.
More of the market is starting to notice.
The shares became dearer on AIR's value read.
The price trend strengthened.
8-KFiled 9 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
TG Therapeutics raised full-year 2026 revenue guidance to ~$1B (from ~$950M) and BRIUMVI U.S. guidance to $915–920M (from $890–905M). Q3 revenue reached $260M. Positive clinical data presented including Phase 3 ENHANCE single-infusion results, Phase 1 subcutaneous bioavailability >60%, and seven-year efficacy follow-up.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 9 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Bicara achieved substantial enrollment in FORTIFI-HN01 pivotal trial for ficerafusp alfa in HPV-negative HNSCC, with interim results expected mid-2027. Cash runway extended to H1 2029. Commercial leadership team in place.
Progress is running ahead of attention.
The price trend weakened.
Sun 22 Nov
CAPR · Capricor Therapeutics, Inc. · Regulatory date
As stated in the filing: “Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026 ●”
Announced by the company in 8-K on 10 Nov 2026
DYN · Dyne Therapeutics, Inc. · Regulatory date
As stated in the filing: “Capricor Therapeutics’ BLA for its cell therapy deramiocel is currently under FDA review with a PDUFA date of November 22, 2026.”
Announced by the company in 10-Q on 5 Nov 2026
SVRA · Savara Inc · Regulatory date
As stated in the filing: “The FDA determined that the Company’s responses to recent information requests by the Agency during its review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026.”
Announced by the company in 10-Q on 9 Nov 2026
Fri 27 Nov
BBIO · BridgeBio Pharma, Inc. · Regulatory date
As stated in the filing: “The first participant was dosed in ASCEND-ATTR, the Phase 3b/4 study to prospectively test disease reversal with Attruby - BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review.”
Announced by the company in 8-K on 29 Oct 2026
Mon 30 Nov
COGT · Cogent Biosciences, Inc. · Regulatory date
As stated in the filing: “Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026 •”
Announced by the company in 8-K on 5 Nov 2026
JBIO · Jade Biosciences, Inc. · Regulatory date
As stated in the filing: “The FDA has also accepted a Biologics License Application for accelerated approval of povetacicept in IgAN, with a Prescription Drug User Fee Act target action date of November 30, 2026.”
Announced by the company in 10-Q on 13 Nov 2026
Wed 2 Dec
ARE · Alexandria Real Estate Equities, Inc. · Investor day
As stated in the filing: “We expect to introduce 2027 guidance and related assumptions at our Investor Day on December 2, 2026, consistent with our historical practice.”
Announced by the company in 8-K on 27 Apr 2026
Thu 3 Dec
EXEL · Exelixis, Inc. · Regulatory date
As stated in the filing: “In February 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.”
Announced by the company in 10-Q on 29 Oct 2026
Tue 8 Dec
GPC · Genuine Parts Co · Investor day
As stated in the filing: “In addition, the Company announced that both Global Automotive and Global Industrial will host separate investor days on December 8, 2026 and December 9, 2026, respectively.”
Announced by the company in 8-K on 9 Sep 2026
LGND · Ligand Pharmaceuticals Inc · Investor day
As stated in the filing: “Ligand will provide an updated 5-year outlook during the Company’s Investor Day on December 8, 2026.”
Announced by the company in 8-K on 14 Jul 2026
Wed 9 Dec
GPC · Genuine Parts Co · Investor day
As stated in the filing: “Investor Days GPC and Motion will host separate investor days in New York City, with GPC’s Investor Day scheduled for December 8, 2026, and Motion’s Investor Day scheduled for December 9, 2026.”
Announced by the company in 8-K on 9 Sep 2026
Sat 12 Dec
ANAB · Anaptysbio, Inc · Regulatory date
As stated in the filing: “FDA target action date (PDUFA) of December 12, 2026, for Quimilza in generalized pustular psoriasis (GPP) GSK and Tesaro Litigation Update •”
Announced by the company in 8-K on 12 Nov 2026
Thu 17 Dec
CORT · Corcept Therapeutics Inc · Regulatory date
As stated in the filing: “Relacorilant for patients with Cushing’s syndrome – Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026 “The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.”
Announced by the company in 8-K on 3 Nov 2026
Mon 23 Nov
MATW · Matthews International Corp · All industries
Annual results due — last year filed 21 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 30%, net income turned to a loss
AIR's current read: News flow Balanced, Gap Low · 0
Tue 24 Nov
BLBD · Blue Bird Corp · Industrials
Annual results due — last year filed 24 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 30%, net income up 408%
AIR's current read: News flow Balanced, Gap Very high · 82
PFLT · PennantPark Floating Rate Capital Ltd. · All industries
Annual results due — last year filed 24 Nov 2025
AIR's current read: News flow Balanced, Gap Very high · 71
Wed 25 Nov
AMTM · Amentum Holdings, Inc. · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2025, against a year earlier): revenue up 66%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 4
ARMK · Aramark · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2025, against a year earlier): revenue up 6%, net income up 23%
AIR's current read: News flow Balanced, Gap Medium · 10
CASH · Pathward Financial, Inc. · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 3%, net income down 31%
AIR's current read: News flow Balanced, Gap Low · 0
CLSK · Cleanspark, Inc. · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2024, against a year earlier): revenue up 129%, net loss widened
AIR's current read: News flow Balanced, Gap Very high · 54
GAP · Gap Inc · All industries
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q3 2024, against a year earlier): revenue down 7%, net income down 23%
AIR's current read: News flow Balanced, Gap Low · 3
ROAD · Construction Partners, Inc. · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 28%, net income up 35%
AIR's current read: News flow Balanced, Gap Low · 7
SJM · J M SMUCKER Co · All industries
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 7%, net loss widened
AIR's current read: News flow Balanced, Gap Low · 7
SMG · Scotts Miracle-Gro Co · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 1%, net income down 25%
AIR's current read: News flow Balanced, Gap Medium · 12
SMTC · Semtech Corp · Semiconductors
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q1 2027, against a year earlier): revenue up 16%, net income up 37%
AIR's current read: News flow Balanced, Gap Low · 0
TFSL · TFS Financial CORP · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q1 2019, against a year earlier): net income up 4%
AIR's current read: News flow Balanced, Gap Medium · 23
Fri 27 Nov
ATKR · Atkore Inc. · Industrials
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 8%, net income down 98%
AIR's current read: News flow Balanced, Gap Low · 0
BJ · BJ's Wholesale Club Holdings, Inc. · All industries
Quarterly results due — last year filed 26 Nov 2025
Last quarter (Q2 2027, against a year earlier): revenue up 16%, net income up 15%
AIR's current read: News flow Balanced, Gap Medium · 18
CENT · Central Garden & Pet Co · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 8%, net income down 5%
AIR's current read: News flow Balanced, Gap Low · 1
CFFN · Capitol Federal Financial, Inc. · Banks
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2020, against a year earlier): net income down 15%
AIR's current read: News flow Balanced, Gap Medium · 10
JJSF · J&J Snack Foods Corp · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 6%, net income down 20%
AIR's current read: News flow Balanced, Gap Low · 0
PD · PagerDuty, Inc. · Software / SaaS
Quarterly results due — last year filed 26 Nov 2025
Last quarter (Q1 2027, against a year earlier): revenue up 1%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 0
SPH · Suburban Propane Partners Lp · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue unchanged, net loss widened
AIR's current read: News flow Balanced, Gap Medium · 21
UTI · Universal Technical Institute Inc · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 7%, net income down 79%
AIR's current read: News flow Balanced, Gap Very high · 57
Mon 30 Nov
SNEX · StoneX Group Inc. · All industries
Annual results due — last year filed 28 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 15%, net income up 102%
AIR's current read: News flow Balanced, Gap Very high · 52
Tue 1 Dec
ESE · Esco Technologies Inc · Industrials
Annual results due — last year filed 1 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 14%, net income up 26%
AIR's current read: News flow Balanced, Gap Very high · 97
Wed 2 Dec
ASAN · Asana, Inc. · Software / SaaS
Quarterly results due — last year filed 2 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 10%, net loss narrowed
AIR's current read: News flow Balanced, Gap Low · 0
UNFI · United Natural Foods Inc · All industries
Quarterly results due — last year filed 2 Dec 2025
AIR's current read: News flow Balanced, Gap Low · 0
VSTS · Vestis Corp · All industries
Annual results due — last year filed 2 Dec 2025
Last quarter (Q3 2025, against a year earlier): revenue down 4%, net income turned to a loss
AIR's current read: News flow Balanced, Gap Low · 1
Thu 3 Dec
BOX · Box Inc · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 9%, net income up 43%
AIR's current read: News flow Balanced, Gap Low · 1
CRWD · CrowdStrike Holdings, Inc. · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 26%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 5
HQY · Healthequity, Inc. · All industries
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 8%, net income up 10%
AIR's current read: News flow Balanced, Gap Low · 0
KSS · KOHLS Corp · All industries
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q3 2024, against a year earlier): revenue down 5%, net income down 39%
AIR's current read: News flow Balanced, Gap Medium · 11
MEI · Methode Electronics Inc · Industrials
Quarterly results due — last year filed 3 Dec 2025
AIR's current read: News flow Balanced, Gap Low · 0
NCNO · nCino, Inc. · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 11%, net income up 145%
AIR's current read: News flow Balanced, Gap Low · 5
THO · Thor Industries Inc · Industrials
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q4 2026, against a year earlier): revenue down 8%, net income down 68%
AIR's current read: News flow Balanced, Gap Low · 4
Fri 4 Dec
AGX · Argan Inc · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 62%, net income up 51%
AIR's current read: News flow Balanced, Gap Low · 9
AMBA · Ambarella Inc · Semiconductors
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 13%, net loss narrowed
AIR's current read: News flow Balanced, Gap Low · 7
BF-B · Brown Forman Corp · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue down 1%, net income up 4%
AIR's current read: News flow Balanced, Gap Low · 0
CXM · Sprinklr, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 1%, net income down 44%
AIR's current read: News flow Balanced, Gap Low · 9
DCI · DONALDSON Co INC · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q4 2026, against a year earlier): revenue up 8%, net income up 13%
AIR's current read: News flow Balanced, Gap Low · 9
FIVE · Five Below, Inc · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2024, against a year earlier): revenue up 14%, net income down 10%
AIR's current read: News flow Balanced, Gap High · 27
GWRE · Guidewire Software, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 27%, net income down 64%
AIR's current read: News flow Balanced, Gap High · 44
NTNX · Nutanix, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 10%, net income up 14%
AIR's current read: News flow Balanced, Gap Medium · 22
REX · REX AMERICAN RESOURCES Corp · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 6%, net income up 336%
AIR's current read: News flow Balanced, Gap Low · 0
SAIC · Science Applications International Corp · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
AIR's current read: News flow Balanced, Gap High · 39
SWBI · Smith & Wesson Brands, Inc. · Industrials
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 32%, net income turned positive
AIR's current read: News flow Balanced, Gap Very high · 87
TITN · Titan Machinery Inc. · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue down 9%, net loss widened
AIR's current read: News flow Balanced, Gap Low · 0
Expected dates come from each company's filing history. They are not forecasts, and companies move them.
Sign in to follow companies
Follow a company and its filings show up here.
Sign inResearch, not tips. Filings come from SEC EDGAR; AIR's read is recomputed every trading day. A price move is shown as a fact beside a filing, never as the reason it is listed.